Identification of dysregulated microRNAs in triple-negative breast cancer (review)

International Journal of Oncology

Volumn 46, Issue 3, 2015, Pages 927-932

  Yang, Fang ^a   Zhang, Wenwen ^a   Shen, Yan ^a   Guan, Xiaoxian ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Epithelial mesenchymal transition; Metastasis; MicroRNAs; Prognosis; Triple negative breast cancer

Indexed keywords

MICRORNA; MICRORNA 100; MICRORNA 125B; MICRORNA 141; MICRORNA 146A; MICRORNA 200A; MICRORNA 200C; MICRORNA 221; MICRORNA 29A; MICRORNA 375; SMALL UNTRANSLATED RNA; TUMOR MARKER;

ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CELL PROLIFERATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION; HUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; TRIPLE NEGATIVE BREAST CANCER; TUMOR INVASION; FEMALE; GENETICS; PATHOLOGY; PROGNOSIS;

CELL PROLIFERATION; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; PROGNOSIS; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84921933294     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2015.2821     Document Type: Article

References (43)

1. Sorlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869-10874, 2001.
2. Di Leva G and Croce CM: Roles of small RNAs in tumor formation. Trends Mol Med 16: 257-267, 2010.
3. Lowery AJ, Miller N, Devaney A, et al: MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res 11: R27, 2009.
4. Gasparini P, Cascione L, Fassan M, et al: microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers. Oncotarget 5: 1174-1184, 2014.
5. Buffa FM, Camps C, Winchester L, et al: microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. Cancer Res 71: 5635-5645, 2011.
6. Iorio MV, Ferracin M, Liu CG, et al: MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65: 7065-7070, 2005.
7. Cochrane DR, Cittelly DM, Howe EN, et al: MicroRNAs link estrogen receptor alpha status and Dicer levels in breast cancer. Horm Cancer 1: 306-319, 2010.
8. Foekens JA, Sieuwerts AM, Smid M, et al: Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. Proc Natl Acad Sci USA 105: 13021-13026, 2008.
9. Mackiewicz M, Huppi K, Pitt JJ, Dorsey TH, Ambs S and Caplen NJ: Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA. Breast Cancer Res Treat 130: 663-679, 2011.
10. Janssen EA, Slewa A, Gudlaugsson E, et al: Biologic profiling of lymph node negative breast cancers by means of microRNA expression. Mod Pathol 23: 1567-1576, 2010.
11. de Rinaldis E, Gazinska P, Mera A, et al: Integrated genomic analysis of triple-negative breast cancers reveals novel microRNAs associated with clinical and molecular phenotypes and sheds light on the pathways they control. BMC Genomics 14: 643, 2013.
12. Calvano Filho CM, Calvano-Mendes DC, Carvalho KC, et al: Triple-negative and luminal breast tumors: differential expression of miR-18a-5p, miR-17-5p, and miR-20a-5p. Tumour Biol 35: 7733-7741, 2014.
13. Farazi TA, Ten Hoeve JJ, Brown M, et al: Identification of distinct miRNA target regulation between breast cancer molecular subtypes using AGO2-PAR-CLIP and patient datasets. Genome Biol 15: R9, 2014.
14. Nassirpour R, Mehta PP, Baxi SM and Yin MJ: miR-221 promotes tumorigenesis in human triple negative breast cancer cells. PLoS One 8: e62170, 2013.
15. Sharma SB, Lin CC, Farrugia MK, et al: microRNAs-206 and -21 cooperate to promote RAS-ERK signaling by suppressing the translation of RASA1 and SPRED1. Mol Cell Biol 34: 4143-4164, 2014.
16. Dong G, Liang X, Wang D, et al: High expression of miR-21 in triple-negative breast cancers was correlated with a poor prognosis and promoted tumor cell in vitro proliferation. Med Oncol 31: 57, 2014.
17. Wang C, Zheng X, Shen C and Shi Y: MicroRNA-203 suppresses cell proliferation and migration by targeting BIRC5 and LASP1 in human triple-negative breast cancer cells. J Exp Clin Cancer Res 31: 58, 2012.
18. Taylor MA, Sossey-Alaoui K, Thompson CL, Danielpour D and Schiemann WP: TGF-beta upregulates miR-181a expression to promote breast cancer metastasis. J Clin Invest 123: 150-163, 2013.
19. Gregory PA, Bert AG, Paterson EL, et al: The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 10: 593-601, 2008.
20. Howe EN, Cochrane DR and Richer JK: Targets of miR-200c mediate suppression of cell motility and anoikis resistance. Breast Cancer Res 13: R45, 2011.
21. Cascione L, Gasparini P, Lovat F, et al: Integrated microRNA and mRNA signatures associated with survival in triple negative breast cancer. PLoS One 8: e55910, 2013.
22. Avery-Kiejda KA, Braye SG, Mathe A, Forbes JF and Scott RJ: Decreased expression of key tumour suppressor microRNAs is associated with lymph node metastases in triple negative breast cancer. BMC Cancer 14: 51, 2014.
23. Wang J, Tsouko E, Jonsson P, et al: miR-206 inhibits cell migration through direct targeting of the actin-binding protein Coronin 1C in triple-negative breast cancer. Mol Oncol 8: 1690-1702, 2014.
24. Eades G, Wolfson B, Zhang Y, Li Q, Yao Y and Zhou Q: lincRNA-RoR and miR-145 regulate invasion in triple-negative breast cancer via targeting ARF6. Mol Cancer Res: Sep 24, 2014. (Epub ahead of print).
25. Humphries B, Wang Z, Oom AL, et al: MicroRNA-200b targets protein kinase Calpha and suppresses triple-negative breast cancer metastasis. Carcinogenesis 35: 2254-2263, 2014.
26. Lee ST, Feng M, Wei Y, et al: Protein tyrosine phosphatase UBASH3B is overexpressed in triple-negative breast cancer and promotes invasion and metastasis. Proc Natl Acad Sci USA 110: 11121-11126, 2013.
27. Jin L, Lim M, Zhao S, et al: The metastatic potential of triple-negative breast cancer is decreased via caloric restriction-mediated reduction of the miR-17∼92 cluster. Breast Cancer Res Treat 146: 41-50, 2014.
28. Liu H, Wang Y, Li X, et al: Expression and regulatory function of miRNA-182 in triple-negative breast cancer cells through its targeting of profilin 1. Tumour Biol 34: 1713-1722, 2013.
29. Toyama T, Kondo N, Endo Y, et al: High expression of microRNA-210 is an independent factor indicating a poor prognosis in Japanese triple-negative breast cancer patients. Jpn J Clin Oncol 42: 256-263, 2012.
30. Kong W, He L, Richards EJ, et al: Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer. Oncogene 33: 679-689, 2014.
31. Shen S, Sun Q, Liang Z, et al: A prognostic model of triple-negative breast cancer based on miR-27b-3p and node status. PLoS One 9: e100664, 2014.
32. Svoboda M, Sana J, Redova M, et al: MiR-34b is associated with clinical outcome in triple-negative breast cancer patients. Diagn Pathol 7: 31, 2012.
33. Radojicic J, Zaravinos A, Vrekoussis T, Kafousi M, Spandidos DA and Stathopoulos EN: MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer. Cell Cycle 10: 507-517, 2011.
34. Deng X, Cao M, Zhang J, et al: Hyaluronic acid-chitosan nanoparticles for co-delivery of miR-34a and doxorubicin in therapy against triple negative breast cancer. Biomaterials 35: 4333-4344, 2014.
35. Tan X, Peng J, Fu Y, et al: miR-638 mediated regulation of BRCA1 affects DNA repair and sensitivity to UV and cisplatin in triple negative breast cancer. Breast Cancer Res 16: 435, 2014.
36. Bisso A, Faleschini M, Zampa F, et al: Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer. Cell Cycle 12: 1679-1687, 2013.
37. Polytarchou C, Iliopoulos D and Struhl K: An integrated transcriptional regulatory circuit that reinforces the breast cancer stem cell state. Proc Natl Acad Sci USA 109: 14470-14475, 2012.
38. Ahmad A, Sarkar SH, Bitar B, et al: Garcinol regulates EMT and Wnt signaling pathways in vitro and in vivo, leading to anti-cancer activity against breast cancer cells. Mol Cancer Ther 11: 2193-2201, 2012.
39. Si L, Jiang F, Li Y, et al: Induction of the mesenchymal to epithelial transition by demethylation-activated microRNA-200c is involved in the anti-migration/invasion effects of arsenic trioxide on human breast cancer cells. Mol Carcinog: Apr 14, 2014 (Epub ahead of print). doi: 10.1002/mc.22157.
40. Johansson J, Berg T, Kurzejamska E, et al: MiR-155-mediated loss of C/EBPbeta shifts the TGF-beta response from growth inhibition to epithelial-mesenchymal transition, invasion and metastasis in breast cancer. Oncogene 32: 5614-5624, 2013.
41. Aceto N, Sausgruber N, Brinkhaus H, et al: Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop. Nat Med 18: 529-537, 2012.
42. Augoff K, McCue B, Plow EF and Sossey-Alaoui K: miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer. Mol Cancer 11: 5, 2012.
43. Krishnan K, Steptoe AL, Martin HC, et al: miR-139-5p is a regulator of metastatic pathways in breast cancer. RNA 19: 1767-1780, 2013.